RNXTRenovoRx Inc. Common Stock
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is che…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 RenovoRx Eyes 2027 TIGeR-PaC Readout as RenovoCath Expands to 21 Centers RenovoRx (NASDAQ:RNXT) executives and physician speakers discussed the treatment landscape for locally advanced pancreatic cancer, the company’s Trans-Arterial Micro-Perfusion, or TAMP, platform, and commercialization progress for its RenovoCath delivery device during a webinar hosted by JonesTradin | ||
RenovoRx Inc (RNXT) (Q2 2026) Earnings Call Highlights: Record Revenue and Strategic Expansion ... RenovoRx Inc (RNXT) reports a 115% year-over-year revenue surge, driven by commercial adoption and full enrollment in its pivotal TIGERPAC trial. | ||
 RenovoRx, Inc. Q2 2026 Earnings Call Summary Moby summary of RenovoRx, Inc.'s Q2 2026 earnings call | ||
RenovoRx Q2 Earnings Call Highlights RenovoRx (NASDAQ:RNXT) reported record second-quarter revenue as it expanded its commercial cancer-center network and advanced its clinical program for locally advanced pancreatic cancer. For the quarter ended June 30, 2026, the company generated revenue of $909,000, up approximately 61% from $563, | ||
 RenovoRx, Inc. (RNXT) Reports Q2 Loss, Beats Revenue Estimates RenovoRx (RNXT) delivered earnings and revenue surprises of +37.50% and +25.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -53.87% and -99.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027 RenovoRx, Inc. (NASDAQ:RNXT) announced Tuesday that it has completed patient enrollment for its Phase 3 TIGeR-PaC study of its targeted drug delivery platform for locally advanced pancreatic cancer (LAPC). The U.S. Food and Drug Administration (FDA)-cleared RenovoCath to isolate blood flow and deliver fluids within the peripheral vascular system, as well as for temporary vessel occlusion during procedures such as chemotherapeutic drug infusion. RenovoRx is evaluating its novel drug-device combin | ||
 Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -81.08% and -20.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates Regenxbio (RGNX) delivered earnings and revenue surprises of +258.33% and +16.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates Editas (EDIT) delivered earnings and revenue surprises of +50.00% and +524.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Travere Therapeutics (TVTX) Reports Q2 Loss, Beats Revenue Estimates Travere (TVTX) delivered earnings and revenue surprises of -164.29% and +10.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||
 Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates Krystal Biotech (KRYS) delivered earnings and revenue surprises of +5.29% and +0.14%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock? | ||